Registered title, quoted from ClinicalTrials.gov
GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma
An open trial on hepatocellular carcinoma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 6 hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 6
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Study siteChinese PLA General Hospital中国人民解放军总医院BeijingHospital page
- Study siteFirst Affiliated Hospital of Zhengzhou University郑州大学第一附属医院ZhengzhouHospital page
- Study siteJiangxi Cancer Hospital江西省肿瘤医院NanchangHospital page
- Study siteSecond Xiangya Hospital中南大学湘雅二医院ChangshaHospital page
- Study siteZhejiang Cancer Hospital浙江省肿瘤医院HangzhouHospital page
- Study siteZhongda Hospital, Southeast University东南大学附属中大医院NanjingHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07209813, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 1
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (1 points)Hide the checklist
18 years to 80 years; sex: all
Registered eligibility fields
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07209813, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Main Inclusion Criteria:
- Voluntarily participates in the study and provides written informed consent.
- Male or female, age ≥ 18 and ≤ 80 years old
- Has pathologically, cytologically, or radiologically confirmed unresectable hepatocellular carcinoma.
- Has CNLC stage II to IIIa disease.
- Has at least one measurable lesion according to mRECIST.
- Child-Pugh class A or B.
- ECOG performance status of 0 - 2.
- Adequate hematologic and organ function.
Main Exclusion Criteria:
- Has a known allergy to the investigational product or related components, including human serum albumin and IL-2.
- Has another incurable malignancy within 5 years before screening or concurrently.
- Has a previous diagnosis of mixed or rare histologic subtypes, including fibrolamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, or combined hepatocellular-cholangiocarcinoma.
- Has received therapy aim to target lesion(s) within 12 weeks before screening.
- Has hepatic encephalopathy within 4 weeks before screening.
- Has clinically symptomatic ascites or pleural effusion requiring drainage, or has undergone thoracic or abdominal fluid drainage.
- Has other active disease.
Quoted from ClinicalTrials.gov, NCT07209813, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07209813, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.